SBIR Phase I: Device for the Activation of Nanoparticle-based Cancer Therapies

SBIR 第一阶段：用于激活基于纳米颗粒的癌症疗法的装置

• 批准号: 0420022
• 负责人: Dennis O'Neal
• 金额: $ 10万
• 依托单位: NANOSPECTRA BIOSCIENCES, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2005-02-28
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0420022&HistoricalAwards=false
• 关键词: SBIR; Phase; Device; Activation; Nanoparticle

This Small Business Innovation Research (SBIR) Phase I research project will develop a device for the in-vivo activation of nanoparticles for the minimally-invasive treatment of solid tumors and for the prophylactic treatment of potential routes of metastatic spread with minimal damage to surrounding tissues. Nanoshells are a new class of nanoparticles that can be designed to absorb light in the near-infrared, wavelengths where tissue is minimally absorptive. Prior nanoshell research has demonstrated its promise for a significant new class of cancer therapies. However, the optical and thermal properties of this new class of materials, the interaction of these properties with the optical properties of human tissue, and, in particular, this interaction at near-infrared wavelengths, are not well understood. This Phase I research will first determine the properties of this new class of materials in vivo and then optimize laser power, laser pulse characteristics (repetition rate, duration and duty cycle), and fiber optic delivery modes.The commercial application of this project will be in the area of cancer therapy. The nanoshell-based therapy is expected to be useful for a broad range of cancer types, with significant advantages relative to other treatments.

该小型企业创新研究（SBIR）第一阶段研究项目将开发一种用于体内激活纳米颗粒的设备，用于实体瘤的微创治疗，以及对转移性扩散的潜在途径进行预防性治疗，对周围组织的损伤最小。纳米壳是一种新型的纳米颗粒，可以被设计为吸收近红外线的光，组织吸收最小的波长。 先前的纳米壳研究已经证明了其对一类重要的新型癌症疗法的前景。 然而，这类新材料的光学和热特性，这些特性与人体组织的光学特性的相互作用，特别是在近红外波长的这种相互作用，还没有得到很好的理解。 第一阶段研究将首先确定这类新材料在体内的特性，然后优化激光功率、激光脉冲特性（重复率、持续时间和占空比）和光纤传输模式，该项目的商业应用将在癌症治疗领域。基于纳米壳的疗法预计可用于广泛的癌症类型，相对于其他治疗方法具有显着优势。